e-Motion: Promoting Emotion Regulation for People Living with Chronic Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot will enroll 30 patients with recently diagnosed chronic or metastatic cancer to compare a guided self-help intervention alone with a combined group plus guided self-help intervention. The interventions draw on emotion-regulation techniques including cognitive behavioral therapy, hypnosis, and positive psychology delivered over 12 weeks, with weekly ecological momentary assessments (EMA). Participants complete baseline and 15-week follow-up questionnaires, a 7-day EMA of emotions, and a post-intervention qualitative interview and satisfaction survey. The primary focus is feasibility, acceptability, and tolerability, with secondary exploratory analyses of changes in psychological symptoms.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Having received a diagnosis of chronic cancer (metastatic breast cancer, metastatic melanoma, metastatic colorectal, metastatic ovarian, metastatic uterine, metastatic endometrial, metastatic prostate, metastatic bladder, metastatic kidney or metastatic testicular cancer, symptomatic multiple myeloma, metastatic non-small cell lung, metastatic mesothelioma or metastatic thymoma) in the past 12 months,
* Having completed at least one active treatment session (e.g., chemotherapy, surgery, radiotherapy, immunotherapy, target therapy).

Exclusion Criteria:

* Having less than one year of life expectancy
* Having more than one treatment line (for triple negative breast cancer, melanoma, gynecological cancer, colorectal cancer, bladder cancer, kidney cancer, non-small cell lung, mesothelioma and thymoma) or two treatment lines (for other breast cancers and testicular cancer) or three treatment lines (for prostate cancer and multiple myeloma),
* Having a diagnosis of oligometastatic cancer,
* Age \< 18 years,
* Non-fluency in French,
* Inability to follow the online intervention,
* Severe cognitive impairment, and severe and/or acute psychiatric disorder.

Where it's running

• H.U.B Institut Jules Bordet
  Brussels, Brussels Capital, Belgium Recruiting
• Institut Jules Bordet, Hôpital universitaire de Bruxelles
  Brussels, Anderlecht, Belgium Not yet recruiting

Study contacts

• Principal investigator: Florence Lewis, PhD — Université Libre de Bruxelles
• Study coordinator: Florence Lewis, PhD
• Email: florence.lewis@hubruxelles.be
• Phone: +32 2 541 73 36

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BCD-248 plus daratumumab in relapsed or refractory multiple myeloma

  This study tests whether adding BCD-248 to daratumumab helps people with relapsed or refractory multiple myeloma who have had prior lines of therapy.

  Recruiting at 16 sites Phase 3 Biocad · Homyel and 15 other locations · NCT07742215

• Immune Fitness in Older Adults with Relapsed or Refractory Multiple Myeloma

  This study checks whether immune health before treatment can predict how well older adults with relapsed or refractory multiple myeloma respond to CAR-T or bispecific antibody therapies.

  Recruiting Jules Bordet Institute · Anderlecht, Brussels Capital and 2 other locations · NCT07674498

• Infectious complications in blood cancer patients treated with bispecific antibodies

  This study tests how often infections occur in adults with blood cancers who are being treated with bispecific antibodies.

  Recruiting at 2 sites Infanta Leonor University Hospital · Madrid, Madrid and 1 other locations · NCT07609576

• Mapping individual multiple myeloma biology to understand relapse and treatment resistance

  This project will test whether combining clinical records with whole-genome and RNA sequencing plus blood tumor markers in people with multiple myeloma can reveal features that explain relapse and treatment resistance.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bo · NCT07582354

• Multi-omics testing for blood and bone marrow cancers

  This project will test a multi-omics lab approach on bone marrow, blood, biopsy and other fluid samples from people with suspected or known hematologic cancers to see if it can better characterize their disease.

  Recruiting Azienda Ospedaliero-Universitaria di Parma · Parma, PR · NCT07445438

• Anonymizing and combining past clinical, genetic, and imaging data from people with multiple myeloma to build AI prediction models.

  This project will try to use already-collected clinical, genetic, and imaging data from adults with multiple myeloma to build AI models that predict disease progression and treatment response, with no new visits or tests required.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bo · NCT07283224

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.